A comparison between intravesical gemcitabine plus docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes.
Rachana Tripathy, Lalit Kumar, Sakshi Agarwal, Anuja Thakur, Mahesh Khairnar, Sameer Trivedi, S N Sankhwar
{"title":"A comparison between intravesical gemcitabine plus docetaxel and intravesical BCG in the treatment of non-muscle invasive naive urinary bladder cancer: A systematic review and meta-analysis of oncological outcomes.","authors":"Rachana Tripathy, Lalit Kumar, Sakshi Agarwal, Anuja Thakur, Mahesh Khairnar, Sameer Trivedi, S N Sankhwar","doi":"10.1016/j.urology.2025.01.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy, recurrence rates, and safety profile of intravesical gemcitabine plus docetaxel versus standard Bacillus Calmette-Guérin (BCG) therapy for treating naïve non-muscle-invasive bladder cancer (NMIBC), focusing on reducing recurrence and progression concerns associated with transurethral resection (TURBT).</p><p><strong>Methods: </strong>Relevant articles were identified and appraised through a structured assessment of the literature. Databases searched included PubMed, Medline, Scopus, and Science Direct.</p><p><strong>Results: </strong>The meta-analysis incorporated a quantitative assessment of 3 original articles. The meta-analysis studies evaluated parameters, including the recurrence rate and safety profile. The I<sup>2</sup> statistics indicated no heterogeneity in recurrence rates between the gemcitabine plus docetaxel (experimental) group and the BCG (control) treatment group. According to the results, the cumulative Odds Ratio for the recurrence rate was 0.72 (95% CI: 0.36-1.47), favoring a slightly lower recurrence rate clinically in the experimental group. The overall effect test yielded a Z-value of 0.89 with a P-value of 0.37, indicating no statistically significant difference in outcome odds between the experimental and control groups.</p><p><strong>Conclusions: </strong>The meta-analysis showed a slightly lower clinical recurrence rate in the intravesical gemcitabine plus docetaxel group than in the intravesical BCG treatment group. The intravesical gemcitabine plus docetaxel group experienced fewer severe side effects. There are limited number of studies available at present. This meta-analysis suggests need of further randomized studies to establish role of intravesical gemcitabine plus docetaxel in NMIBC.</p>","PeriodicalId":23415,"journal":{"name":"Urology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urology.2025.01.004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the efficacy, recurrence rates, and safety profile of intravesical gemcitabine plus docetaxel versus standard Bacillus Calmette-Guérin (BCG) therapy for treating naïve non-muscle-invasive bladder cancer (NMIBC), focusing on reducing recurrence and progression concerns associated with transurethral resection (TURBT).
Methods: Relevant articles were identified and appraised through a structured assessment of the literature. Databases searched included PubMed, Medline, Scopus, and Science Direct.
Results: The meta-analysis incorporated a quantitative assessment of 3 original articles. The meta-analysis studies evaluated parameters, including the recurrence rate and safety profile. The I2 statistics indicated no heterogeneity in recurrence rates between the gemcitabine plus docetaxel (experimental) group and the BCG (control) treatment group. According to the results, the cumulative Odds Ratio for the recurrence rate was 0.72 (95% CI: 0.36-1.47), favoring a slightly lower recurrence rate clinically in the experimental group. The overall effect test yielded a Z-value of 0.89 with a P-value of 0.37, indicating no statistically significant difference in outcome odds between the experimental and control groups.
Conclusions: The meta-analysis showed a slightly lower clinical recurrence rate in the intravesical gemcitabine plus docetaxel group than in the intravesical BCG treatment group. The intravesical gemcitabine plus docetaxel group experienced fewer severe side effects. There are limited number of studies available at present. This meta-analysis suggests need of further randomized studies to establish role of intravesical gemcitabine plus docetaxel in NMIBC.
期刊介绍：
Urology is a monthly, peer–reviewed journal primarily for urologists, residents, interns, nephrologists, and other specialists interested in urology
The mission of Urology®, the "Gold Journal," is to provide practical, timely, and relevant clinical and basic science information to physicians and researchers practicing the art of urology worldwide. Urology® publishes original articles relating to adult and pediatric clinical urology as well as to clinical and basic science research. Topics in Urology® include pediatrics, surgical oncology, radiology, pathology, erectile dysfunction, infertility, incontinence, transplantation, endourology, andrology, female urology, reconstructive surgery, and medical oncology, as well as relevant basic science issues. Special features include rapid communication of important timely issues, surgeon''s workshops, interesting case reports, surgical techniques, clinical and basic science review articles, guest editorials, letters to the editor, book reviews, and historical articles in urology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
